- Conditions
- Breast Cancer, Malignant Neoplasm of Breast
- Interventions
- Palbociclib, Aromatase inhibitor, Ribociclib, Abemaciclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 193
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pregnancy Related, Atopic Dermatitis
- Interventions
- Ruxolitinib Cream, TCS
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 14 Years and older · Female only
- Enrollment
- 5,621 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Morrisville, North Carolina
- Conditions
- Chronic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,006,361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Cambridge, Massachusetts • Ann Arbor, Michigan
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Not listed
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- Rochester, Minnesota • St Louis, Missouri • Manhasset, New York + 5 more
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS)
- Interventions
- Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
- Combination Product · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
- Conditions
- Atrial Fibrillation
- Interventions
- Observational
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 38,499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Bronchiolitis Obliterans Syndrome
- Interventions
- Not listed
- Lead sponsor
- Zambon SpA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Columbus, Ohio • Dallas, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- Interferon beta-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Walnut Creek, California • Shreveport, Louisiana + 5 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Fluciclovine (18F)
- Radiation
- Lead sponsor
- Blue Earth Diagnostics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Non-metastatic Castration-resistant Prostate Cancer
- Interventions
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Opioid Overdose
- Interventions
- Observation only
- Other
- Lead sponsor
- Member Companies of the Opioid PMR Consortium
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 808,455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Wilmington, Delaware • Boston, Massachusetts • Portland, Oregon + 1 more
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
- Interventions
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Device · Other
- Lead sponsor
- Peerbridge Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Pasadena, California • Nashville, Tennessee
- Conditions
- Drug Resistant Epilepsy, Refractory Epilepsy
- Interventions
- Participants are not assigned an intervention as part of the study.
- Other
- Lead sponsor
- NeuroOne Medical Technologies Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Miami, Florida • Livingston, New Jersey • New Brunswick, New Jersey
- Conditions
- Psoriasis
- Interventions
- Deucravacitinib, Systemic psoriasis medications, No systemic medications
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Lawrenceville, New Jersey
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,708 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Multiple Locations, Connecticut
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 17,418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- natalizumab, dimethyl fumarate
- Biological · Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 40 more
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- Predictive models (data collection)
- Other
- Lead sponsor
- Sophia Genetics SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Worcester, Massachusetts • Rochester, Minnesota + 3 more
- Conditions
- Breast Cancer
- Interventions
- Screening
- Device
- Lead sponsor
- Siemens Medical Solutions
- Industry
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2020
- U.S. locations
- 1
- States / cities
- Malvern, Pennsylvania
- Conditions
- Vaccine Compliance
- Interventions
- Observational
- Other
- Lead sponsor
- Jaye Shyken, MD
- Other
- Eligibility
- 14 Years to 55 Years · Female only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Opioid Use Disorder, Opioid Overdose, Death
- Interventions
- No intervention, observational retrospective study
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 27,257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- X-Linked Adrenoleukodystrophy (X-ALD), Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD)
- Interventions
- Allo-HSCT
- Genetic
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Industry
- Eligibility
- Up to 17 Years · Male only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 3 more
- Conditions
- Retinitis Pigmentosa, Leber Congenital Amaurosis
- Interventions
- OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Vericiguat (Verquvo, BAY1021189)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey